112 related articles for article (PubMed ID: 3406634)
41. Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: validation of telequantification based on global scene segmentation.
Ferrer Roca OF; Ramos A; Diaz Cardama A
Anal Cell Pathol; 1995 Sep; 9(2):151-63. PubMed ID: 7492518
[TBL] [Abstract][Full Text] [Related]
42. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
44. Hormone receptors in cervical intraepithelial neoplasia.
Bloch B
Obstet Gynecol Surv; 1979 Nov; 34(11):868-9. PubMed ID: 523046
[TBL] [Abstract][Full Text] [Related]
45. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
47. Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix.
Suzuki Y; Nakano T; Arai T; Morita S; Tsujii H; Oka K
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1229-34. PubMed ID: 10889376
[TBL] [Abstract][Full Text] [Related]
48. Steroid receptors and histological types in cervical cancer.
Fujimoto J; Tamaya T; Watanabe Y; Arahori K; Sato S; Okada H
Asia Oceania J Obstet Gynaecol; 1986 Dec; 12(4):541-8. PubMed ID: 3827733
[No Abstract] [Full Text] [Related]
49. Oestrogen and progesterone receptors in carcinoma of the cervix.
Harding M; McIntosh J; Paul J; Symonds RP; Reed N; Habeshaw T; Stewart M; Leake RE
Clin Oncol (R Coll Radiol); 1990 Nov; 2(6):313-7. PubMed ID: 2278888
[TBL] [Abstract][Full Text] [Related]
50. Cytoplasmic estrogen and progesterone receptors in primary cervical carcinoma: clinical and histopathologic correlates.
Gao YL; Twiggs LB; Leung BS; Yu WC; Potish RA; Okagaki T; Adcock LL; Prem KA
Am J Obstet Gynecol; 1983 Jun; 146(3):299-306. PubMed ID: 6859140
[TBL] [Abstract][Full Text] [Related]
51. Estrogen and progesterone receptor sites in malignancies of the uterine cervix, vagina, and vulva.
Ford LC; Berek JS; Lagasse LD; Hacker NF; Heins YL; DeLange RJ
Gynecol Oncol; 1983 Feb; 15(1):27-31. PubMed ID: 6822366
[TBL] [Abstract][Full Text] [Related]
52. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma.
Creasman WT; Soper JT; McCarty KS; McCarty KS; Hinshaw W; Clarke-Pearson DL
Am J Obstet Gynecol; 1985 Apr; 151(7):922-32. PubMed ID: 3985057
[TBL] [Abstract][Full Text] [Related]
53. Is it safe to prescribe hormonal contraception and replacement therapy to patients with premalignant and malignant uterine cervices?
Sadan O; Frohlich EP; Driscoll JA; Apostoleris A; Savage N; Zakut H
Gynecol Oncol; 1989 Aug; 34(2):159-63. PubMed ID: 2753422
[TBL] [Abstract][Full Text] [Related]
54. [Histochemical study of estrogen and progesterone receptors in cervical carcinoma].
An HX; Zhang L; Cai GR
J Tongji Med Univ; 1992; 12(1):60-4. PubMed ID: 1619698
[TBL] [Abstract][Full Text] [Related]
55. Estrogen and progesterone receptor assay in carcinoma of the cervix with monoclonal antibodies.
Kim JW; Sung HR; Kim DK; Song CH
Gynecol Oncol; 1992 Dec; 47(3):306-10. PubMed ID: 1473742
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of estrogen receptors in cancer of the uterine cervix.
Martin JD; Hännel R; McCartney AJ; Woodings T
N Engl J Med; 1982 Feb; 306(8):485. PubMed ID: 7057851
[No Abstract] [Full Text] [Related]
57. Absence of estrogen and progesterone receptors in glassy cell carcinoma of the cervix.
Atlas I; Gajewski W; Falkenberry S; Granai CO; Steinhoff MM
Obstet Gynecol; 1998 Jan; 91(1):136-8. PubMed ID: 9464737
[TBL] [Abstract][Full Text] [Related]
58. Immunocytochemical analysis of receptors for estrogen and progesterone in fine needle aspirates from anal epidermoid carcinoma.
Goldman S; Skoog L; Wilking N
Dis Colon Rectum; 1992 Feb; 35(2):163-5. PubMed ID: 1735318
[TBL] [Abstract][Full Text] [Related]
59. Steroid hormone receptors in laryngeal carcinoma.
Virolainen E; Tuohimaa P; Aitasalo K; Kyttä J; Vanharanta-Hiltunen R
Otolaryngol Head Neck Surg; 1986 Apr; 94(4):512-7. PubMed ID: 3086815
[TBL] [Abstract][Full Text] [Related]
60. Prognostic importance of progesterone and estrogen receptors in cancer of the uterine cervix.
Potish RA; Twiggs LB; Adcock LL; Prem KA; Savage JE; Leung BS
Cancer; 1986 Oct; 58(8):1709-13. PubMed ID: 3756793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
